In this regard, it has been reported that the humanized monoclonal antibody trastuzumab used for breast cancer treatment can interact with SDC4, resulting in reduced proliferation, invasion, and angiogenesis of anoikis-resistant endothelial cells [162]. Here, SDC4 is linked to breast cancer.